Comments
Natco Pharma (Canada) Inc., Canada, a subsidiary of Natco Pharma Ltd, has entered into a settlement agreement with Celgene (now part of Bristol-Myers Squibb) for the product Lenalidomide capsules in Canada.
“The terms of the agreement are confidential as per the agreement,” the Hyderabad-based Natco Pharma said in a release issued on Friday.
Natco’s scrip trading at ₹676.75 on the BSE on Friday, almost flat over the previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.